Physician profile
Mitchell P Engle
NPI 1790946051
$72,065.65
in general payments reported to CMS, 2019-2025
45 companies · $37K in 2025
The $37K reported for 2025 was more than what 99% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,160 · 2020: $3,063 · 2021: $2,439 · 2022: $3,079 · 2023: $12K · 2024: $11K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $25K · Consulting Fee: $20K · Food and Beverage: $8,575 · Travel and Lodging: $6,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,650.00 |
| Consulting Fee | $20,125.00 |
| Food and Beverage | $8,575.14 |
| Travel and Lodging | $6,974.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $36,179.73 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Nalu Medical, INC. | $25,635.26 | 2021-2025 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $1,818.39 | 2020-2021 | |
| Nevro Corp. | $1,626.84 | 2020-2024 | Senza |
| Abbott Laboratories | $1,156.80 | 2019-2025 | Eterna, Proclaim |
| Relievant Medsystems, INC. | $1,005.45 | 2021-2023 | Intracept |
| Saluda Medical Americas, INC. | $834.42 | 2022-2025 | Evoke Scs, Evoke |
| Globus Medical, INC. | $490.67 | 2025 | Senza, Vyrsa Fix, Vyrsa V1 |
| Medtronic, INC. | $388.44 | 2021-2025 | Synchromedii, Inceptiv, Intellis Adaptivestim |
| Medtronic USA, INC. | $326.02 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $228.83 | 2019-2022 | |
| Spr Therapeutics, INC | $221.07 | 2021-2023 | Sprint Pns System |
| Curonix LLC | $188.55 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Collegium Pharmaceutical, INC. | $188.34 | 2019-2024 | Belbuca |
| Spinefrontier, INC. | $182.04 | 2020 |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Engle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.